The International CCN Society

Log in | Register

Contact Us

Katia Scotlandi

Katia Scotlandi, Ph.D. 
Department of Experimental Oncology,
Othopedic Rizzoli Institute
40136-Bologna, Italy
Tel.: 39-051-6366 760
FAX: 39-051-6366 763
mailto:katia.scotlandi@ior.it

Present Position

  • Chief of UO: Development of Biomolecular Therapies
  • Professor of Molecular Biology - University of Bologna, Italy

Societies

  • Board of Directors of the Italian Society of Cancer
    and of Italian Association for Cell Culture.
  • Founder of the Italian Sarcoma Group
    Member of:
  • American Association for Cancer Research
  • European Association for Cancr Research
  • Connective Tissue Oncology Society
  • Insulin-like growth factor Society
  • International Society for Insulin-like Growth Factor Research
  • International Bone & Mineral Society
  • American Association for Cell Biology
  • International CCN Society

Research Themes

  • Definition of targeted and differentiation therapies in sarcomas
  • Matricellular proteins in the resistance and progression of tumors
  • Cross-talk between IGF system and tumor microenvironment
  • Gene expression profiling and miRNAs regulating mesenchymal stem cell differentiation

Selected Recent Publications

  • Zucchini C, Manara MC, Pinca RS, De Sanctis P, Guerzoni C, Sciandra M, Lollini PL, Cenacchi G, Picci P, Valvassori L, Scotlandi K.
    CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity.
    Oncogene, 2013.
  • Manara MC, Garofalo C, Ferrari S, Belfiore A, Scotlandi K.
    Designing novel therapies against sarcomas in the era of personalized medicine and economic crisis.
    Curr Pharm Des. 2013 Feb 4. Review.
  • Nakatani F, Ferracin M, Manara MC, Ventura S, Del Monaco V, Ferrari S, Alberghini M, Grilli A, Knuutila S, Schaefer KL, Mattia G, Negrini M, Picci P, Serra M, Scotlandi K.
    miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemosensitivity and malignancy.
    J Pathol. 2012 Apr;226(5):796-805.
  • Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A, Pandini G, López-Guerrero JA, Schaefer KL, Belfiore A, Picci P, Scotlandi K.
    Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling.
    Oncogene. 2011 Jun 16;30(24):2730-40.
  • Rocchi A, Manara MC, Sciandra M, Zambelli D, Nardi F, Nicoletti G, Garofalo C, Meschini S, Astolfi A, Colombo MP, Lessnick SL, Picci P, Scotlandi K.
    CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis.
    J Clin Invest. 2010 Mar 1; 120(3):668-80.
  • Manara MC, Nicoletti G, Zambelli D, Ventura S, Guerzoni C, Landuzzi L, Lollini PL, Maira SM, García-Echeverría C, Mercuri M, Picci P, Scotlandi K.
    NVP-BEZ235 as a new therapeutic option for sarcomas.
    Clin Cancer Res. 2010 Jan 15;16(2):530-40.
  • Zambelli D, Zuntini M, Nardi F, Manara MC, Serra M, Landuzzi L, Lollini PL, Ferrari S, Alberghini M, Llombart-Bosch A, Piccolo E, Iacobelli S, Picci P, Scotlandi K.
    Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP).
    Int J Cancer. 2010 Jan 1; 126(1):41-52.
  • Perbal B, Lazar N, Zambelli D, Lopez-Guerrero JA, Llombart-Bosch A, Scotlandi K, Picci P.
    Prognostic relevance of CCN3 in Ewing sarcoma.
    Hum Pathol. 2009 Oct; 40(10):1479-86.
  • Scotlandi K, Remondini D, Castellani G, Manara MC, Nardi F, Cantiani L, Francesconi M, Mercuri M, Caccuri AM, Serra M, Knuutila S, Picci P.
    Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome.
    J Clin Oncol. 2009 May 1;27(13):2209-16.
  • Perbal B, Zuntini M, Zambelli D, Serra M, Sciandra M, Cantiani L, Lucarelli E, Picci P, Scotlandi K.
    Prognostic value of CCN3 in osteosarcoma.
    Clin Cancer Res. 2008 Feb 1; 14(3):701-9.